Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Madrigal Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $490.14M, up 154.4% year over year. For fiscal 2025 it was $388.53M, up 64.1% from the year before. Over ten years it grew 66.1% a year on average. The highest annual figure on record is $388.53M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $388.53M | +64.1% |
| FY2024 | Dec 31, 2024 | $236.72M | -13.1% |
| FY2023 | Dec 31, 2023 | $272.35M | +11.0% |
| FY2022 | Dec 31, 2022 | $245.44M | +19.6% |
| FY2021 | Dec 31, 2021 | $205.16M | +11.0% |
| FY2020 | Dec 31, 2020 | $184.81M | +155.5% |
| FY2019 | Dec 31, 2019 | $72.32M | +184.9% |
| FY2018 | Dec 31, 2018 | $25.39M | +4.1% |
| FY2017 | Dec 31, 2017 | $24.39M | +53.1% |
| FY2016 | Dec 31, 2016 | $15.93M | +556.4% |
| FY2015 | Dec 31, 2015 | $2.43M | -96.4% |
| FY2014 | Dec 31, 2014 | $68.21M | -5.1% |
| FY2013 | Dec 31, 2013 | $71.86M | +45.4% |
| FY2012 | Dec 31, 2012 | $49.41M | +19.2% |
| FY2011 | Dec 31, 2011 | $41.46M | +3.0% |
| FY2010 | Dec 31, 2010 | $40.25M | -21.2% |
| FY2009 | Dec 31, 2009 | $51.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $91.18M | +68.6% |
| Q1 FY2026 | Mar 31, 2026 | $108.69M | +146.1% |
| Q4 FY2025 | Dec 31, 2025 | $116.27M | +353.3% |
| Q3 FY2025 | Sep 30, 2025 | $174.00M | +153.1% |
| Q2 FY2025 | Jun 30, 2025 | $54.08M | -23.9% |
| Q1 FY2025 | Mar 31, 2025 | $44.17M | -38.0% |
| Q4 FY2024 | Dec 31, 2024 | $25.65M | -63.7% |
| Q3 FY2024 | Sep 30, 2024 | $68.74M | -3.1% |
| Q2 FY2024 | Jun 30, 2024 | $71.09M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $71.24M | +14.6% |
| Q4 FY2023 | Dec 31, 2023 | $70.64M | -0.1% |
| Q3 FY2023 | Sep 30, 2023 | $70.95M | +3.9% |
| Q2 FY2023 | Jun 30, 2023 | $68.61M | +17.3% |
| Q1 FY2023 | Mar 31, 2023 | $62.15M | +29.7% |
| Q4 FY2022 | Dec 31, 2022 | $70.74M | +33.8% |
| Q3 FY2022 | Sep 30, 2022 | $68.27M | +24.4% |
| Q2 FY2022 | Jun 30, 2022 | $58.50M | +13.3% |
| Q1 FY2022 | Mar 31, 2022 | $47.93M | +4.7% |
| Q4 FY2021 | Dec 31, 2021 | $52.89M | -1.0% |
| Q3 FY2021 | Sep 30, 2021 | $54.87M | +3.0% |
| Q2 FY2021 | Jun 30, 2021 | $51.63M | +15.5% |
| Q1 FY2021 | Mar 31, 2021 | $45.77M | +37.0% |
| Q4 FY2020 | Dec 31, 2020 | $53.43M | +114.5% |
| Q3 FY2020 | Sep 30, 2020 | $53.29M | +174.0% |
| Q2 FY2020 | Jun 30, 2020 | $44.69M | +186.6% |
| Q1 FY2020 | Mar 31, 2020 | $33.40M | +169.9% |
| Q4 FY2019 | Dec 31, 2019 | $24.91M | +180.8% |
| Q3 FY2019 | Sep 30, 2019 | $19.45M | +213.1% |
| Q2 FY2019 | Jun 30, 2019 | $15.59M | +205.2% |
| Q1 FY2019 | Mar 31, 2019 | $12.37M | +138.0% |
| Q4 FY2018 | Dec 31, 2018 | $8.87M | +36.2% |
| Q3 FY2018 | Sep 30, 2018 | $6.21M | -7.0% |
| Q2 FY2018 | Jun 30, 2018 | $5.11M | -25.0% |
| Q1 FY2018 | Mar 31, 2018 | $5.20M | +18.7% |
| Q4 FY2017 | Dec 31, 2017 | $6.51M | +17.9% |
| Q3 FY2017 | Sep 30, 2017 | $6.68M | -14.4% |
| Q2 FY2017 | Jun 30, 2017 | $6.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.81M | – |
See a number that looks wrong?